FBR Capital Reiterates Outperform as Pandora (P) Announces Warner Music Deal
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Pre-Open Stock Movers 09/16: (DEPO) (INTC) (GPRO) Higher; (NVAX) (DB) (ORCL) Lower (more...)
September 16, 2016 9:29 AM EDTToday's After-Hours Movers:
Novavax, Inc., (Nasdaq: NVAX) 83% LOWER; announced topline data from two clinical trials of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in older adults. The Resolve trial, a Phase 3 trial of our RSV F Vaccine in 11,856 older adults (60 years of age and older), did not meet the pre-specified primary or the secondary efficacy objectives, and did not demonstrate vaccine efficacy. Consistent with our previous clinical experience, the vaccine was well... More
After-Hours Stock Movers 09/15: (SCOR) (CAR) (P) Higher; (NVAX) (DB) (ORCL) Lower (more...)
September 15, 2016 7:16 PM EDTToday's After-Hours Movers:
Novavax, Inc., (Nasdaq: NVAX) 83% LOWER; announced topline data from two clinical trials of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in older adults. The Resolve trial, a Phase 3 trial of our RSV F Vaccine in 11,856 older adults (60 years of age and older), did not meet the pre-specified primary or the secondary efficacy objectives, and did not demonstrate vaccine efficacy.... More
Pandora (P), Warner Music Group Enter Recorded Music Licensing Agreement
September 15, 2016 4:44 PM EDTPandora (NYSE: P) announced a direct licensing agreement for recorded music with Warner Music Group. This agreement enables both companies to support artists and satisfy the full range of music listening experiences for consumers.
Warner has been a tremendous partner to Pandora and were thrilled to expand the... More
Pandora (P) Debuts Lower-Cost Pandora Plus Service
September 15, 2016 8:02 AM EDTPandora (NYSE: P) launched Pandora Plus, a one-of-a-kind, ad-free radio experience with dramatically increased functionality. For just $4.99 per month, this innovative listening experience includes more skips, replays and an ingenious solution for offline listening that elegantly handles issues with lost connectivity and cellular data usage. This unique marriage of design and functionality, at a very affordable price, marks yet another milestone in Pandoras journey to create the most personal music experience in the world, giving listeners greater flexibility and control, while allowing for the endless discovery that listeners love so much.
Were always... More
Pandora (P): New Product Pushes Profitability Farther Out - Needham
September 15, 2016 6:56 AM EDTNeedham & Company analyst, Laura Martin, reiterated her Buy rating on shares of Pandora (NYSE: P) but cut profit estimates for 2017 due to the additional dilution from the new agreements with record labels and the impact of incremental trial subscriptions.
The two key... More
Canaccord Genuity Boosts PT on Pandora (P) to $18; Affirms at 'Buy'
September 14, 2016 9:40 AM EDTCanaccord Genuity lifts its price target on Buy-rated Pandora Media (NYSE: P) from $14 to $18 following new deals announced on Tuesday.
The firm commented, Pandora announced long-awaited and much-anticipated direct sound recording licensing deals with Universal Music Group, Sony Music, and over 40 independent... More
Oppenheimer Remains Sidelined as Pandora (P) Announces Licensing Deals
September 14, 2016 9:28 AM EDTOppenheimer reiterated a Perform rating on Pandora (NYSE: P) following the company's announced licensing deals with Sony Music, Universal Music, Merlin, and 40+ independent record labels. The new (on-demand) service is expected to launch domestically in 4Q:16, and will pay 65%-70% of its potential revenue to... More
SunTrust Robinson Humphrey Reiterates Buy on Pandora (P) Following Announced Direct Deals
September 14, 2016 8:16 AM EDTSunTrust Robinson Humphrey reiterated a Buy rating and $18.00 price target on Pandora (NYSE: P) following the company's announced U.S.-only direct deals with most major labels.
Analyst Robert Peck commented, "Pandora announced direct deals with most major labels, which would allow it... More
Pandora (P) PT Raised to $14 at Mizuho; One of Most Likely to be Acquired
September 14, 2016 7:24 AM EDTMizuho Securities analyst Neil Doshi raised his price target on Pandora (NYSE: P) to $13.00 (from $11.00) but maintained a Neutral rating. The target was increased on the new direct deals, as well as its potential as an M&A target.
"Given that Pandora announced that it signed direct deals with Sony, Universal, Merlin, and 30+ indie labels for its ondemand... More
Pandora (P): Direct Licensing Deals, Another Step Towards Profitability - Wedbush
September 14, 2016 7:16 AM EDTWedbush analyst, Michael Pachter, reiterated his Outperform rating on shares of Pandora (NYSE: P) on the belief that if the company can convert 2 million Pandora One subscribers to on-demand and attract both 1 2 million new U.S. on-demand subscribers, and 1 2 million international ondemand subscribers in... More